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Summary
Follicular lymphoma (FL) is an indolent disease, but 30-40% of cases undergo histologic
transformation to an aggressive malignancy, typically represented by diffuse large B cell
lymphoma (DLBCL). The pathogenesis of this process remains largely unknown. Using whole-
exome sequencing and copy-number analysis, here we show that the dominant clone of FL and
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transformed FL (tFL) arise by divergent evolution from a common mutated precursor through the
acquisition of distinct genetic events. Mutations in epigenetic modifiers and anti-apoptotic genes
are introduced early in the common precursor, while tFL is specifically associated with alterations
deregulating cell-cycle progression and DNA-damage responses (CDKN2A/B, MYC, TP53), as
well as with aberrant somatic hypermutation. The genomic profile of tFL shares similarities with
that of germinal center B-cell-type de novo DLBCL, but also displays unique combinations of
altered genes, with diagnostic and therapeutic implications.
Introduction
Follicular lymphoma (FL) is the second most common type of B cell non-Hodgkin
lymphoma, comprising ~25% of all new diagnoses (Swerdlow et al., 2008) (http://
seer.cancer.gov/statistics/). Although initially indolent and responsive to a variety of
treatments, this disease remains largely incurable (Kridel et al., 2012). One particularly
compelling problem in the clinical history of FL is its histologic transformation to a more
aggressive malignancy, typically represented by a diffuse large B cell lymphoma (DLBCL)
(Montoto and Fitzgibbon, 2011). FL transformation has been reported to occur in 16 to 70%
of patients over time, with a consensus rate of 3% per year, and is associated with a mean
survival post-transformation of less than 2 years (Montoto and Fitzgibbon, 2011). Thus,
there is a strong need for an increased understanding of both the dynamics of tumor clonal
evolution and the mechanisms that are responsible for transformation, which may in turn be
translated into more effective therapies.
Although the process of transformation to DLBCL was originally described several decades
ago, few studies have specifically addressed this question in longitudinal series with
documented clonal relationship between the two phases (Lossos and Gascoyne, 2011).
Current knowledge of the biology of transformation suggests the involvement of
heterogeneous genetic, epigenetic and microenvironment-dependent factors, most notably
mutations of TP53 (Lo Coco et al., 1993; Sander et al., 1993), genetic and/or epigenetic
inactivation of the p16 tumor suppressor gene (Pinyol et al., 1998), translocations
deregulating the BCL6 proto-oncogene (Akasaka et al., 2003), alterations involving
chromosome 1p36, (Martinez-Climent et al., 2003) and changes in MYC expression (Lossos
et al., 2002). Additionally, analysis of selected genes in few cases revealed an association
between progression to DLBCL and aberrant somatic hypermutation (ASHM) (Rossi et al.,
2006), a mechanism of genetic instability resulting from the abnormal functioning of the
physiologic SHM process that operates in germinal center (GC) B cells (Pasqualucci et al.,
2001). However, these findings were based on small number of cases and a candidate-gene
approach, as opposed to an unbiased, genome-wide analysis. Thus, the biological
mechanisms that are responsible for the lethal event of FL transformation remain
incompletely understood.
The present study was aimed at examining the history of clonal evolution during FL
transformation to DLBCL (tFL) and at comprehensively identifying molecular determinants
that underlie this process.
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Divergent evolution of FL and tFL from a common mutated precursor
To investigate whether transformation of FL evolves as a linear process, i.e. through the
emergence of an aggressive subclone from the initial dominant FL population, or derives
from the divergent evolution of an ancestral common precursor cell (CPC) that acquired
distinct mutations to become a FL or a tFL, we integrated massively parallel whole-exome
sequencing (WES) and genome-wide high-resolution single nucleotide polymorphism (SNP)
array analysis in a “discovery panel” of sequential FL and tFL biopsies obtained from 12
patients, including 4 with available matched normal DNA (Table S1, Figure S1 and Table
S2). In all cases, investigation of the rearranged immunoglobulin (Ig) genes by Sanger
sequencing and/or SNP array analysis confirmed the clonal relationship between the two
phases, while the inferred copy number value at the segment of deletional recombination
within the Ig loci was used to quantify the percentage of tumor cells in the biopsy
(Bergsagel and Kuehl, 2013), allowing to normalize the data for clonal representation (Table
S1). FISH analysis was used to assess the presence of chromosomal translocations affecting
BCL2, MYC and BCL6.
We extrapolated the evolutionary history of transformation by defining genomic alterations
that are present in the dominant clone of both pre- and post-transformation specimens
(“shared lesions”), and contrasting them to those that are present exclusively in the FL or
tFL biopsy (“phase-specific lesions”). This analysis allows to discriminate between a linear,
sequential model, where the tFL dominant clone will maintain all lesions present in the FL
dominant clone, together with additional tFL-acquired alterations, and a divergent evolution
model, which postulates the existence of lesions that are unique to the dominant clone of the
FL or the tFL, in addition to the set of shared alterations (Experimental Procedures and
Figure S1).
Overall, we found 52 clonally represented, shared copy number aberrations (CNAs)
(average, 4.3/sample; range, 0-19/sample), and 234 shared single nucleotide variants
(SNVs), including silent and non-silent mutations (average, 38.5/sample in the 4 patients
with matched normal DNA; in the remaining 8 pairs, shared SNVs were only considered if
affecting 52 genes that have been previously validated as functional targets of somatic
mutations in lymphoid malignancies, because of the exceedingly high number of variants
that are predicted in the absence of matched normal DNA, likely reflecting private SNPs not
reported in public databases)(see Experimental Procedures). The presence of shared genetic
alterations was documented in all sample pairs analyzed, confirming the original clonal
relationship between the FL and tFL sample (Figure 1, left panel).
In addition to shared lesions, all tFL cases harbored unique mutations and CNAs that were
not present in the major FL clone at diagnosis, indicating acquisition during the
transformation process or selection of a minor subclone, the entity of which was below the
detection threshold of the methodologies used. The number of tFL-specific lesions (n=707
SNVs and 291 CNAs, including 119 losses and 172 gains) was widely heterogeneous across
different patients, ranging from 24 to 160 per case (average, 83/sample) (Figure 1, right
panel; see also Figure S2A and Table S3). Importantly, unique, clonally represented events
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were also detected in 10/12 baseline FL biopsies (n=327, including 229 SNVs and 98
CNAs) (Figure 1, middle panel and Figure S2A). The presence of FL-specific lesions was
not due to CN loss or copy-neutral loss of heterozygosity (cnLOH) affecting the same region
in the sequential tFL biopsy, as documented by both SNP array and WES analysis. Thus,
these events had been acquired independently by the dominant FL clone, consistent with
divergent evolution.
Evidence of non-linear evolution was also observed at the individual gene level. As an
example, both FL and tFL of patient #23 harbored biallelic MLL2 mutations in the dominant
clone, but only one of the two events (S286fs) was shared between the pre- and post-
transformation biopsy, consistent with its presence in the common ancestor clone, while
distinct mutations were detected in the second allele of the FL (R2687*) and tFL
(R280_splice) specimen, indicating that they had been acquired independently by the
ancestor clone during evolution to these two diseases (Figure S2B-D).
Overall, 10/12 patients analyzed (83.3%; 95% CI: 55%-95%) showed a mutation pattern
suggestive of divergent evolution, indicating that this is the predominant mode in the history
of FL transformation (Figure 2). The remaining two patients (#8 and #12) did not harbor FL-
specific events; furthermore, a significant proportion of tFL-specific lesions (13/63 in
patient #8 and 34/57 in patient #12) could be detected at low frequencies (4-15%) in the FL
specimen, suggesting that the tFL arose from a minor subclone within the dominant FL
population, which subsequently acquired additional mutations in a linear evolution pattern
(Figure 2 and Table S3).
With one exception (patient #17), the number of events acquired by the tFL dominant clone
(including CNAs and SNVs) was significantly higher than that acquired by the FL dominant
clone, ranging from >30-fold in case #6 to 2-fold in case #4 (p<0.005), and underscoring the
genomic complexity of the tFL genome (Figure 1 and Figure S3A). Of note, at least one of
these 10 patients did not receive any treatment between the original FL diagnosis and
transformation, indicating that the higher mutation load of tFL does not simply reflect the
consequence of the mutagenic effect or the selective pressure of chemotherapy. In at least 2
patients, several chromosomes displayed convoluted intra-chromosomal rearrangements due
to alternating gains and losses of genomic material, frequently accounting for over 10
switches per chromosome (Figure S3B and Table S4). While the sequencing approach
adopted in our study (WES, as opposed to whole genome) prevents from distinguishing true
chromothripsis from localized lesions that occurred progressively (Korbel and Campbell,
2013), these data highlight a remarkable genomic instability in tFL cases compared to both
FL and other lymphoid malignancies (Fabbri et al., 2011; Mullighan et al., 2007; Rossi et
al., 2012).
Collectively, these findings support a divergent evolution model in a significant proportion
of patients undergoing transformation, whereby FL and tFL arise from a common mutated
ancestor through the independent acquisition of distinct genetic lesions.
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In order to identify lesions potentially relevant for transformation among the large number
of candidates that emerged from the analysis of the “discovery panel” (773 unique genes,
including those targeted by non-silent SNVs, small indels, and/or CNAs if within minimal
common regions involving a maximum of 3 loci), we extended the WES and SNP array
analysis to 27 additional tFLs (“screening panel”; combined, 39 tFLs). These data were then
interrogated for the presence of recurrent alterations, a common readout for functionally
relevant genes, and by three independent analytical methods for the identification of key
targets of functional genomic alterations: i) MutComFocal, a recently developed
computational algorithm that isolates candidate cancer genes from high throughput CN and
SNV data (Trifonov et al., 2013a); ii) MutSigCV, a tool that analyzes SNV data to identify
genes mutated more often than expected by chance (Lawrence et al., 2013); and iii) GISTIC,
a computational approach identifying significant targets of somatic CNAs.
Figure 3 illustrates the overall proportion of tFL cases harboring genetic lesions in genes
altered at ≥10% frequency and recognized as functionally relevant targets by at least one of
the three independent approaches, with few additional genes of functional annotation within
the same pathway (see also Figures S4-S6, Table S5 for the full list of genes found mutated
in ≥10% of cases, and Table S6). Genes are grouped into biological categories and are
annotated to indicate whether alterations were also found in the diagnostic FL biopsy
(available in 24 of the 39 cases) or were predominantly acquired/selected at transformation.
Collectively, these aberrations point to a number of biological programs/signaling pathways
that are either dysregulated early in the putative FL/tFL precursor cell (i.e., “shared” lesions)
or selected during transformation (“tFL-specific” lesions).
Genetic lesions shared by FL and tFL
The most commonly affected genes in both FL and tFL were those encoding for histone/
chromatin modification enzymes, including methyltransferases and acetyltransferases (36/39
of cases, 92.3%). In line with previous findings in unselected FL (Morin et al., 2010; Morin
et al., 2011; Pasqualucci et al., 2011a; Pasqualucci et al., 2011b), the H3K4
trimethyltransferase MLL2 was mutated in 26/39 tFL cases (66.7%), with 36 truncating
events and 9 missense mutations (Figure 3, Figure S4, Figure S6 and Table S7). These
lesions were already present at FL diagnosis in all but one patient, and were never lost at
transformation, consistent with an early acquisition by the CPC. The activity of the MLL2-
containing complex was also impaired by mutually exclusive alterations of KDM6B,
encoding for a H3K4 histone demethylase interacting with MLL2 (n=3/39 cases, including 2
SNVs and one homozygous deletion), and MLL3 (n=3/39 cases)(Figure S4, Figure S6 and
Table S7). Additionally, nearly one third of tFL cases (n=10/39, 25.6%) harbored EZH2
gain-of-function mutations that almost invariably replace the hotspot tyrosine residue Y641
within the protein SET domain (n=9/10)(Table S7). EZH2 mutations have been reported in
7% unselected FL and 22% de novo GCB-DLBCL (Morin et al., 2010; Morin et al., 2011),
where they increase H3K27 levels through altered substrate specificity.
Another class of chromatin modifiers was represented by the acetyltransferases CREBBP
(n=21/39 patients, 53.8%; 19 point mutations and 2 focal deletions) and EP300 (6/39 cases,
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15.4%, of which 5 mutated and one deleted)(Figures 3, S4, and S6). In both genes, the
mutation pattern was highly reminiscent of what has been reported in unselected FL and de
novo DLBCL with respect to both the inactivating nature of the lesions, the evidence of
mutational hotspots (R1446 in 5 patients, F1484 in 2 patients, Y1503 in 2 patients, and
ΔS1680 in 3 patients)(Table S7), and the predominantly monoallelic distribution (17/19
affected cases), indicating a haploinsufficient tumor suppressor role (Pasqualucci et al.,
2011a).
Programmed cell death was the second largest program dysregulated in both FL and tFL,
and thus presumably in the common ancestor clone. In addition to BCL2 translocations,
detected in 27/33 tFL (81.8%) and invariably shared between the two phases (n=18
informative pairs), all t(14;18) positive cases harbored multiple somatic point mutations
within the ~2Kb region downstream to the BCL2 transcription initiation sites (Figure 3,
Figure S4 and Table S7), reflecting the activity of the AID-dependent SHM process driven
by the juxtaposed Ig enhancer (Lohr et al., 2012; Saito et al., 2009).
The FAS gene was disrupted in 13/39 tFL (33.3%) due to inactivating mutations (n=4/39,
10.2%) and genomic deletions (n=9/39, 23.1%, including 2 focal homozygous events)
(Figure 3 and Figure S4). In the 3 affected patients with available pre- and post-
transformation biopsy, these lesions were always detectable at FL diagnosis, suggesting their
presence in the putative CPC (Table S7). Interestingly, none of 23 unselected FL exomes
harbored FAS mutations, arising the possibility that these lesions represent an early marker
for transformation. FAS encodes for a receptor protein that acts as a major mediator of
apoptosis in GC B cells carrying low affinity and self-reactive antigen receptors (van Eijk et
al., 2001). With the exception of one amino acid substitution removing the initiating
methionine (M1T), all FAS mutations (Y232*, P217_splice and D317V) cluster in exons
7-9, which encode for the protein intracytoplasmic tail (Table S7). This domain is required
for the assembly of the death-inducing signaling complex, and its truncation will result in
the functional loss of normal FAS signaling by a dominant negative effect (Siegel et al.,
2000), as documented in patients with autoimmune lymphoproliferative syndrome
(Holzelova et al., 2004). A deleterious effect was also predicted for the D317V amino acid
change based on the PolyPhen 2 algorithm (Table S7). FAS was identified as a relevant
target of genomic deletions by two independent algorithms, including GISTIC (Figure S5
and Table S6) and MutComFocal.
Taken together, these findings identify the disruption of pathways affecting chromatin
modifier functions and resistance to apoptosis as recurrent lesions common to FL and tFL,
and thus presumably occurring early during the initial clonal expansion of the putative
precursor clone.
Genetic lesions specifically associated with tFL
The most common genomic aberration specifically acquired during progression to tFL was
the loss of CDKN2A/B, two tumor suppressor genes whose protein products (p14-ARF, p16-
INK4A and p15-INK4B) play major roles as negative regulators of cell cycle G1
progression and as stabilizers of the tumor suppressor p53 (Sherr, 2004). Overall, 46.1% of
tFL (n=18/39) carry genomic aberrations affecting these loci, including 17 CN losses (n=6
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heterozygous and 11 homozygous) (Figure 4A) and a nonsense C72* mutation combined
with cnLOH (Figure S4 and Table S7). In most deleted cases (n=10/17), the loss of genetic
material encompassed ≤3 genes, identifying a minimal common region smaller than 10kb
and exquisitely restricted to the CDKN2A/B locus. Biallelic CDKN2A/B alterations were
never present at FL diagnosis, indicating a specific role during transformation (Figure 4B).
The loss of CDKN2A/B may impinge on different biological programs, including DNA
damage responses (via the p14-ARF/p53 pathway) and cell cycle regulation (via the RB/p16
tumor suppressive pathway). As expected, immunohistochemical staining for p16 expression
confirmed its complete loss in the neoplastic lymphocytes of all biallelically deleted tFL
cases (n=8/8); however, 2/3 monoallelically deleted cases and a significant proportion of
wild-type cases (n=5/15 tFL, 33.3%) were also p16-negative (not shown), suggesting the
involvement of epigenetic mechanisms of inactivation. Although the limited number of
cases prevents statistical analysis, CDKN2A/B biallelic lesions tend to be mutually exclusive
with biallelic deletions/mutations of TP53, observed in 7/39 tFL cases (17.9%), but absent at
FL diagnosis (n=3 informative cases)(Figure 4C). These observations suggest that
CDKN2A/B loss may contribute to FL transformation by affecting both cell cycle regulation
and p53-dependent DNA damage responses, thus promoting genomic instability. Consistent
with this hypothesis, patients exhibiting dysregulation of the ARF/p53 axis via biallelic
alterations of CDKN2A/B and/or TP53 were characterized by a significantly higher number
of CNAs compared to patients that harbor wild-type alleles (average n=45.0 vs 20.5, Mann
Whitney U test, p=0.03)(Figure 4D).
Genetic lesions deregulating MYC, namely chromosomal translocations (n=6/24 tFL with
available FISH data, 25.0%), copy number gains/amplifications (n=13/39, 33.3%), and point
mutations reflecting the activity of ASHM (Figure 5, Figure S4 and Table S7) were the
second commonest tFL-specific lesions. While low copy number gains could be
occasionally observed in the original FL biopsy, high CN amplifications, translocations and
point mutations were either completely absent (n=13 cases) or only detected in a minor
subclone within the dominant FL population (patient #8). Deregulated MYC oncogenic
activity may provide multiple advantages to the cancer cell through its pleiotropic function
in cell growth, metabolism and genetic instability.
Also enriched at transformation were biallelic mutations and/or deletions encompassing
B2M (n=5/39) and CD58 (n=2/39), two genes involved in the control of immune-recognition
by cytotoxic T lymphocytes and natural killer cells, respectively, and previously shown to be
recurrently inactivated in de novo DLBCL (Challa-Malladi et al., 2011) (Figure 3, Figure
S4, Table S6 and Table S7). B2M genomic aberrations were specifically acquired/selected at
transformation (n=3 informative cases) and, accordingly, B2M as well as CD58 were not
mutated in 23 unselected FL exomes analyzed, implicating escape from immune
surveillance as a contributor to the transformation process.
Finally, multiple point mutations, small deletions and duplications were identified in the 5’
sequences of several recognized ASHM target genes, including PIM1, PAX5, RhoH/TTF,
MYC, BCL7A, CIITA and SOCS1 (overall, 34/39 cases, 87.1%) (Figure 6). These lesions
display typical features of AID-mediated activity (Figure S7) and, depending on the
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genomic configuration of the involved locus, were variably distributed in coding and/or
noncoding sequences. These changes were not detected in the pre-transformation biopsy,
indicating that they had been specifically acquired or selected at transformation (Figure 6).
These data point to a malfunction of SHM occurring late in the disease, although the
prolonged exposure of the precursor cell to the potentially deleterious environment of the
GC reaction may also favor the accumulation of lesions.
Non phase-specific lesions
A number of genetic alterations were variably observed as shared or phase-specific events,
suggesting heterogeneous contributions to disease pathogenesis. Consistent with previous
reports (Lossos and Gascoyne, 2011), TNFRSF14, encoding for a member of the TNF
receptor superfamily which signals to T cells with stimulatory or inhibitory effects
depending on the ligand was disrupted in 22/39 tFL (56.4%) and 9/17 FL cases (52.9%), due
to a combination of truncating mutations (n=14, distributed in 11 tFL and 3 FL), genomic
deletions (n=15 tFL and 6 FL), and cnLOH (n=4 tFL and 1 FL) (Figure S4 and Table S7).
Importantly, all mutated tFL cases had lost the residual wild-type allele due to deletion or
cnLOH. While multiple other candidate genes are encompassed by the large heterozygous
deletions affecting chromosomal region 1p36.31, this typical pattern of biallelic inactivation
documented the specific involvement of TNFRSF14 in these lesions (Figure S4).
STAT6, a DNA binding transcription factor implicated in IL4 and IL13-mediated responses,
was the target of heterozygous somatic point mutations in 9/39 (23.1%) tFL cases. Analysis
of the diagnostic FL biopsy revealed the presence of the same mutation in 3/5 available
cases, while the remaining 2 had acquired this lesion at transformation; STAT6 mutations
were observed in unselected FL cases (1/23, 4.3%), consistent with a role in both disease
phases. Of note, all STAT6 mutations cluster within the protein DNA binding domain,
identifying a mutational hotspot of possible functional relevance at residue D419, which was
substituted to G (4 cases), H (one case) and Y (one case) (Figure S4 and Table S7), as
previously reported in primary mediastinal B cell lymphoma (Ritz et al., Blood)
Several genes encoding for core histones were also frequently mutated in both tFL (n=16/39,
41.0%) and FL (n=6/12, 50%), with HIST1H1E being the most common target (n=7/39 tFL,
17.9%; 2/12 FL, 16.6%, and 2/23 unselected FL, 8.7%)(Table S5 and S7). In addition, >10%
of tFL and FL harbored loss-of-function (nonsense and frameshift) mutations disrupting the
ARID1A (n=7/39, 17.9% vs 2/23, 8.7%) and ARID1B (n=1/39, 2.6% vs 0/23) genes, two
components of the SWI/SNF chromatin remodeling complex, which was recently shown to
take part in maintaining the pluripotency of stem cells as well as in reprogramming somatic
cells (Ho et al., 2009).
Finally, a number of recurrent lesions are expected to interfere with signaling pathways that
are triggered in response to engagement of the BCR or CXCR4 receptors; these include
oncogenic mutations of CARD11 and CD79B [4/39 tFL (10.3%) and 3/39 tFL (7.7%),
respectively], alterations in negative and positive regulators of NF-κB [TNFAIP3,
biallelically lost in 6/39 tFL, and TRAF2- and Nck-interacting kinase (TNIK) mutated in
4/39 cases], truncating mutations of GNA13 (n=8/39 tFL, 20.5% vs 1/23 unselected FL,
4.3%), and point mutations of FOXO1 (n=6/39 tFL, 15.4% vs 0/23 unselected FL)(Table S5
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and S7); deregulation of the latter three genes may impinge on the PI3K pathway as well as
on RhoGTPase responses, and has been observed in de novo DLBCL (Morin et al., 2013;
Trinh et al., 2013). Taken together, these results point to several signaling pathways that are
recurrently dysregulated in FL and/or tFL, although their individual contribution is not
specifically restricted to a discrete phase of disease pathogenesis (see Discussion).
The genomic landscape of tFL is unique but more related to GCB-DLBCL
In order to determine whether tFL and de novo DLBCL represent pathogenically different
diseases, we compared the genomic profile of the 39 tFLs to that of 102 de novo DLBCLs
representative of the two major molecular subtypes, i.e. germinal center B cell like (GCB)
and activated B cell like (ABC) DLBCL (Alizadeh et al., 2000). When analyzed by
unsupervised hierarchical clustering using the frequency of aberrations at 36 informative
targets, tFL appears to be closer to GCB- than to ABC-DLBCL (see Methods). Common
features of the two diseases include the presence of BCL2 rearrangements, REL
amplifications, EZH2, GNA13, and TNFRSF14 mutations (Morin et al., 2010; Morin et al.,
2011; Pasqualucci et al., 2011b), along with the absence of typical ABC-DLBCL specific
aberrations (MYD88 mutations and PRDM1 inactivation) (Mandelbaum et al., 2010; Morin
et al., 2013; Ngo et al., 2011; Pasqualucci et al., 2006) (Figure 7). However, unique
combinations of genetic lesions were found in tFL, which are otherwise never observed in
GCB-DLBCL (e.g., biallelic deletions of CDKN2A/B: 28.2% of tFL cases vs 0% of GCB-
DLBCL, p<0.01). Moreover, tFL tends to be enriched in alterations that are generally less
frequent in de novo DLBCL, such as STAT6 mutations (23.1% vs 2.4%), ARID1A mutations
(12.8% vs 3.9%) and FAS mutations/deletions (33.3% vs 8%). Particularly, although
observed in both tFL and de novo DLBCL, aberrations of MLL2, CREBBP and BCL2 were
significantly enriched in cases derived from FL transformation compared to GCB-DLBCL
(p=0.02, 0.0006 and 0.0001), suggesting that at least a subset of GCB-DLBCL arises from
the precursor cell postulated by the results described above. In conclusion, the genome of
tFL appears more similar to GCB-DLBCL, but overall unique as compared to both subtypes
of de novo DLBCL.
Discussion
This study reports a comprehensive characterization of the coding genome of tFL, an
aggressive disease with dismal prognosis, the pathogenesis of which has been so far
incompletely understood. Our goal was to take advantage of systematic, genome-wide
approaches to address key questions related to this aggressive condition, which remained
unanswered or had been previously only studied by examining individual genes. These
include: i) tracing the evolutionary history of the dominant clone during transformation from
indolent FL; ii) providing an assessment of the range and frequency of genetic aberrations
that are associated with this event; iii) identifying novel genomic changes as potential
genetic drivers of transformation; and iv) elucidating the relationship between DLBCL
deriving from FL transformation and DLBCL arising de novo.
The first finding of our study is that, while all FL/tFL sample pairs have a clear clonal
relationship, the dominant tFL clone arises in most patients from a mutated CPC through the
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acquisition of independent genetic events, consistent with divergent evolution. The existence
of this CPC cannot be physically demonstrated, but can be postulated based on the presence
of a set of lesions that are shared between FL and tFL, and is consistent with previous
studies based on the analysis of the rearranged Ig genes (Carlotti et al., 2009) as well as with
recent work on FL progression (Green et al., 2013). Our study does not address the
topography of the tFL clone and/or the intraclonal architecture of these tumors, which
require the backtracking of tFL-specific lesions in the diagnostic FL sample by ultra high-
deep sequencing analysis (Ding et al., 2012; Walter et al., 2012; Welch et al., 2012). Thus,
further studies will be needed to clarify whether the tFL clone temporally developed after
FL diagnosis or can be already detected as a minor subclone within the FL diagnostic
sample. Notably, the two most prominent programs deregulated in the precursor clone –
epigenetic modifications and resistance to apoptosis–represent actionable targets with a
number of drugs already being tested in the clinic (e.g. BCL2 inhibitors, histone deacetylase
inhibitors, and EZH2 inhibitors)(Sherr, 2004). If these lesions are essential to the survival of
the fully transformed tumor cells, and if the tFL clone is not already present at FL diagnosis,
the development of combination regimens incorporating drugs that specifically target this
group of alterations in early stages of FL may lead to the elimination of the precursor clone,
possibly preventing transformation.
Our study reveals that, while the genome of tFL is significantly more complex compared to
FL, no unifying genetic lesion is selected during transformation to DLBCL. Nonetheless, the
recurrent alteration of genes involved in the control of cell cycle progression (CDKN2A/B,
MYC) and DNA damage responses (alternative biallelic loss of TP53 and CDKN2A) suggest
that loss of genetic stability and deregulated proliferation are critical steps in tFL
development. Lesions affecting CDKN2A/B have been observed in several terminally
aggressive lymphoid malignancies, including relapsed acute lymphoblastic leukemia
(Mullighan et al., 2008), Richter syndrome (Fabbri et al., 2013) and ABC-DLBCL (Lenz et
al., 2008), consistent with a central role in the acquisition of a more aggressive phenotype.
The existence of tFL cases that lack p16 expression despite being devoid of CDKN2A
genetic lesions suggests an even broader involvement of this pathway through alternative
epigenetic mechanisms (e.g. promoter hypermethylation or post-transcriptional
modifications). Furthermore, the inactivation of epigenetic modifiers such as CREBBP/
EP300 and MLL2 may also contribute to the deregulation of cell growth and DNA damage
responses by interfering with p53 acetylation and activation (Pasqualucci et al., 2011a).
The genomic complexity of tFL appears to be remarkably high with respect to other
hematologic malignancies, as exemplified by the presence of numerous CNAs and the
evidence of ASHM. The latter may represent a major mechanism for transformation, as
previously suggested for de novo DLBCL (Pasqualucci et al., 2001). Interestingly, although
the physiologic SHM process is known to operate in FL (Bahler and Levy, 1992), ASHM
was only observed in the dominant clone of tFL, pointing to a disruption occuring late
during evolution to or selection of a more aggressive disease. While the analysis presented
here did not uncover any apparent lesions in genes that are directly involved in SHM, the
alteration of histone marks owing to genetic lesions in histone modification/chromatin
remodeling enzymes may induce chromatin conformation changes that favor the
Pasqualucci et al. Page 10













accessibility of non-physiologic genomic regions to the AID mutator. Thus, further studies
interrogating the entire genome as well as the epigenome of this cancer will be necessary to
conclusively address this question.
Finally, and consistent with observations obtained by gene expression profiling, our data
highlight tFL as a distinct disease that, although more similar to GCB-DLBCL, harbors
unique combinations of oncogenic and tumor suppressor lesions compared to de novo
DLBCL Previous studies have suggested that transformation proceeds through two distinct
pathways: one characterized by a high-proliferation signature and the second where T cell
and follicular dendritic-associated genes predominate (Davies et al., 2007; Lossos et al.,
2002). We did not observe statistically significant mutual exclusion between genetic lesions
affecting these two classes of mutated genes (e.g., MYC and CDKN2A/B vs TNFRSF14 and
STAT6). However, integrated genomic and transcriptional profiling of larger cohorts of
patients will be needed to address this question. The unique tFL genomic landscape,
combining together alterations that are specific to GCB- and ABC-DLBCL, as well as
lesions that are uncommon in de novo DLBCL, could be responsible at least in part for its
poor response to standard anti-DLBCL regimens. The results herein suggest the potential
usefulness of combining current immuno-chemotherapeutic regimens that harness the
proliferative and genetically unstable phenotype of tFL with more specific approaches
targeting some of the pathways recurrently altered in tFL, as it could be the case for CDK4/6




A discovery panel of 24 sequential fresh-frozen biopsies (12 pairs) obtained at FL diagnosis
and at transformation to DLBCL (Table S1) and a screening panel of 27 tFL samples were
selected based on the criteria described in Supplemental Information, and used for WES and
SNP6.0 array analysis. Matched normal DNA was available for 4 of the 12 discovery pairs,
and was documented to lack contaminating tumor cells by PCR amplification of the clonally
rearranged tumor-associated Ig genes as well as by SNP array analysis of the corresponding
loci. Using these 12 pairs, we estimate a 99% probability of detecting mutations that affect
genes at 30% prevalence and 93% probability for genes at 20% prevalence.
Whole exome capture and next generation sequencing
Purified high molecular weight genomic DNA (~3μg) from the 12 FL samples and the 39
tFL samples (n=12 from the discovery panel and 27 from the screening panel) was enriched
in protein-coding sequences by using the Agilent SureSelect Human 51Mb All Exon V4 kit
(Agilent Technologies, Santa Clara, CA), according to the manufacturer's protocol. The
resulting target-enriched pool was normalized and combined (4-plex) before high-
throughput paired-end (2 × 100 bp) sequencing on the Illumina HiSeq2000 System at
Centrillion Biosciences, Inc. The analysis produced on average 67.5 million passed-filter
paired-end reads/sample (range: 51.7-111.6) (Table S2). After filtering for duplicate reads
(defined as reads with identical start and orientation), sequences were aligned to the
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reference human genome hg19 assembly (GRCh37) using the Burrows-Wheeler Aligner
(BWA) tool version 0.5.9. The mean coverage depth (i.e., the mean number of reads
covering the target exome of a haploid reference) was 80.8X (range: 45.8-119.4), with on
average 89.3% of the captured region covered at >10X (range: 83.8-93.4), and 73.9%
covered at >30X (range: 53.9-84.5)(Table S2). Sequence variants, including nucleotide
substitutions and small insertions/deletions, were obtained independently for each tumor and
normal sample using the SAVI (Statistical Algorithm for Variant Identification) algorithm
(Trifonov et al., 2013b), and were independently validated by conventional Sanger
sequencing as described in Supplemental Experimental Procedures.
Dominant clonal analysis
For the purpose of reconstructing the history of clonal evolution during FL transformation to
DLBCL, we first estimated the percentage of tumor cells in the biopsy based on the inferred
CN value at the clonally rearranged Ig loci (i.e., the region of intrachromosomal deletional
recombination at 14q32, 2p11 and 11q22). The allelic frequency of each SNV was then
corrected for the fraction of tumor cells in the biopsy by calculating its expected frequency,
the 95% confidence intervals from its observed frequency, the total depth at the variant
position and the tumor content of the sample, assuming a binomial distribution.
Mutations were classified as clonal if the fraction of variant reads (upon correction for the
percentage of tumor cells in the specimen) was >20, and subclonal otherwise. Because this
analysis focuses on the history of the dominant tumor clone, only SNVs that were clonally
represented in at least one disease phase were considered. SNVs were then assigned to one
of the following three categories: i) shared mutations, i.e. mutations that are detected in the
major clone of both diseases phases; ii) FL-specific mutations, i.e. mutations present in the
major clone of the FL phase and either completely absent or present at subclonal levels in
the paired tFL specimen, provided the difference in the corrected frequencies between the
two phases was statistically significant at p-value <0.05 (as explained below), and after
excluding that its absence in the paired tFL specimen was not due to CN loss or cnLOH
involving the same genomic region; and iii). tFL-specific mutations, i.e. mutations present in
the major clone of the tFL phase and absent or subclonal in the FL biopsy, provided the
difference in the corrected frequencies between the two phases was statistically significant at
p-value <0.05, and could not be explained by CN loss or cnLOH in the latter. To assess
whether the difference in frequencies between the two phases was significant, we considered
a binomial distribution and calculated the probability of observing the variant in the pre-
transformation (or post-transformation) phase, given the coverage depth at that position, the
observed frequency of variant reads in the paired sample, and the estimated tumor content of
the samples. WES and SNP6.0 analysis were used to exclude that the absence of FL-specific
SNVs in the longitudinal tFL biopsy was due to recombination events, such as CN losses or
cnLOH affecting the same region; the few mutations belonging to this category were
conservatively classified as “shared” (in cases with paired normal DNA) or were excluded
(in cases without paired normal DNA). Mutations that were clonally represented in the tFL
phase, but could be detected in a small fraction of reads in the FL phase (with p<0.05) were
defined as DLBCL-specific since they most likely reflect a pre-existing smaller clone within
the FL major clone, while mutations that were clonally represented in the FL phase but were
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also detected in a small fraction of the tFL population (with p<0.05) were considered as FL-
specific since they may reflect residual FL cells amidst the DLBCL clone, which were not
selected during progression and expansion.
High-density SNP array analysis, sequencing analysis of ASHM target genes, FISH and
immunohistochemistry analysis were all performed as previously described and their
detailed protocols can be found in Supplemental Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FL and tFL arise from a common mutated precursor clone by divergent evolution
Epigenetic modifiers and anti-apoptotic genes are mutated in the common precursor
Biallelic disruption of CDKN2A/B and deregulation of MYC are specific to tFL
tFL displays a unique genomic profile with only partial similarity to DLBCL
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Figure 1. FL and tFL display shared and unique genomic aberrations
Overall load of genetic lesions identified by WES and CN analysis in the dominant clone of
the 12 discovery cases. Color codes denote distinct types of aberrations (Tx, translocation).
*In cases lacking matched normal DNA, shared SNVs are limited to those affecting 52
selected genes with well-established roles in lymphomagenesis (see Methods); thus, the total
number of genetic lesions in these patients (right column) likely represents an underestimate.
FL-specific SNVs that could be due to genomic loss or cnLOH of the same region in the tFL
phase were excluded.
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Figure 2. FL and tFL arise through divergent evolution in most patients
Inferred models of clonal evolution during FL transformation. The original B cell clone is on
top; blue and red circles depict the FL and tFL clones, respectively, while green, dotted
circles represent the postulated common mutated precursor cell (CPC). In the linear model
(2/12 patients analyzed), the tFL dominant clone originates directly from the FL dominant
clone after acquisition of additional mutations. In the divergent model (10/12 patients
analyzed), the FL and tFL dominant clones derive from a CPC through the independent
acquisition of distinct mutations. In both scenarios, the tFL dominant clone may be present
as a minor subclone already at the time of the FL biopsy. ABC, mutations shared between
FL and tFL; DEF, mutations unique to the FL dominant clone; GHI, mutations unique to the
tFL dominant clone.
Pasqualucci et al. Page 19













Figure 3. Recurrently mutated genes in tFL
Proportion of tFL cases (n=39) carrying genetic lesions (SNVs and CNAs) in genes altered
at ≥10% frequency and deemed significant by one of three independent algorithms (see
Supplemental Information and Table S5); additional genes of functional relevance in the
same pathways are also shown. Deletions and gains were only computed if defining MCRs
of aberration encompassing maximum 3 genes. Green shade highlights alterations
consistently shared between the FL and tFL sample, and red shade identifies alterations
enriched in tFL (asterisks, p<0.05 when comparing tFL frequency vs unselected FL
frequency; note that TP53 was considered as a tFL-specific target despite its borderline p
value, because invariably unmutated in the diagnostic FL sample of all 3 informative tFL
cases, and because of the broad literature data. The remaining genes did not appear to be
phase-specific or could not be unequivocally assigned to a given category because of the
relatively small numbers (for the full list of SNVs found in >5% of tFL cases, see Table S7).
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Figure 4. Biallelic loss of CDKN2A/B is specifically acquired during transformation
(A) Segmentation data from 18 DLBCL samples harboring CDKN2A/B deletions, visualized
using the Integrative Genomics Viewer software (http://www.broadinstitute.org/igv). Each
track represents one sample, where white denotes a normal (diploid) copy number, blue
indicates a region of copy number loss, and red corresponds to a region of copy number
gain. The inferred copy number, and the corresponding color intensity, may vary across
samples due to the presence of non-tumor cells infiltrating the biopsy. Individual genes in
the region are aligned in the bottom panel, and the boxed area (defined by the red bar at the
top) corresponds to the CDKN2A/B locus. (B) dChipSNP heatmap showing median-
smoothed log2 CN ratio in 14 tFL biopsies harboring CDKN2A/B deletions, including 6 with
matched FL biopsies, and two control DNAs (N). A vertical blue bar indicates the location
of the CDKN2A/B loci. (C) Relative distribution of biallelic lesions affecting CDKN2A/B
and TP53. Columns correspond to individual patients, and the genomic status of the two
genes is color-coded as indicated. (D) Samples carrying biallelic alterations of CDKN2A/B
and/or TP53 are characterized by a significantly higher number of CN aberrations (Mann-
Whitney U test, p=0.03).
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Figure 5. Recurrent genetic lesions of MYC in tFL
(A) GISTIC analysis of CN gains in FL and tFL cases (see also Figure S5). (B) Percentage
of cases carrying genetic lesions of MYC in FL and tFL. (C) FISH analysis using a MYC
break-apart probe in tFL#40. (D) IHC analysis of MYC expression in the pre- and post-
transformation biopsy of the same patient.
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Figure 6. ASHM is associated with transformation
(A) Proportion of cases harboring mutations in known ASHM targets; the BCL6 intron 1
region, a physiologic target of SHM in GC B cells, and the BCL2 sequences, which
accumulate mutations in translocated alleles under the influence of the juxtaposed IGH
promoter, are shown as controls. The three mutated FL cases harbored one single event
each.
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Figure 7. tFL displays a unique genomic profile that partially overlaps with GCB-DLBCL
Percentage of cases carrying the indicated genetic lesions in de novo DLBCL (top panel:
green bars, GCB-DLBCL; n=50; red bars, ABC-DLBCL; n=52) and tFL (bottom panel,
black bars; n=39). Asterisks indicate statistically significant differences (one-tailed Fisher's
exact test; * p<0.05, ** p<0.01). Mutation frequencies for SGK1 and GNA13 are derived
from Morin et al., Nature 2011. M, mutation (missense, nonsense, frameshift, splice-site); D,
deletion; G, gain; AMP, amplification; M/D*, biallelic inactivation; Tx, translocation.
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